Denali Therapeutics Inc. (DNLI)
| Market Cap | 5.81B |
| Revenue (ttm) | 357.07M |
| Net Income (ttm) | 55.93M |
| Shares Out | 121.29M |
| EPS (ttm) | 0.46 |
| PE Ratio | 103.41 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 292,270 |
| Open | 47.69 |
| Previous Close | 47.80 |
| Day's Range | 46.81 - 48.70 |
| 52-Week Range | 40.12 - 93.94 |
| Beta | 1.86 |
| Analysts | Buy |
| Price Target | 85.50 (+79.7%) |
| Est. Earnings Date | Nov 4, 2021 |
About DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small mol...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for DNLI stock is "Buy." The 12-month stock price forecast is 85.50, which is an increase of 79.74% from the latest price.
News
New Strong Sell Stocks for October 12th
ONEM, DNLI, FMC, GPL, and LGO have been added to the Zacks Rank #5 (Strong Sell) List on October 12, 2021.
Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program
Denali Therapeutics Inc (NASDAQ: DNLI) announced data from the Phase 1 trial evaluating DNL343, eIF2B activator, in 95 healthy volunteers. DNL343 was generally well tolerated for up to 14 days of dosing...
Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotroph...
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...
Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 a...
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cros...
Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer
Proven commercial leader with broad global experience in building and running commercial organizations and successfully launching products for people with neurological and rare diseases Proven commercia...
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS
— Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS — — Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS —
Denali Therapeutics Inc. (DNLI) Up 5.7% Since Last Earnings Report: Can It Continue?
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?
President And CEO Of Denali Therapeutics Sold $1.00 Million In Stock
Ryan Watts, President and CEO at Denali Therapeutics (NASDAQ:DNLI), made a large insider sell on September 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and E...
Biotech Takeovers Moved at Snail's Pace in 2nd Quarter
Clovis Oncology Inc. ( CLVS , Financial) and Denali Therapeutics Inc. ( DNLI , Financial) are among the most likely biotechs to be acquired, according to industry publications. Denali, by far, would be ...
Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN
Preclinical studies show enhanced brain uptake of progranulin can be achieved using Denali's Transport Vehicle to cross the blood-brain barrier Preclinical studies show enhanced brain uptake of progranu...
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -35.14% and -28.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...
Will Denali Therapeutics Inc. (DNLI) Report Negative Q2 Earnings? What You Should Know
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Denali Therapeutics Stock Is Sinking Today
The company reported interim results from a phase 1/2 study of its experimental Hunter syndrome drug.
Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the L...
SOUTH SAN FRANCISCO, Calif., July 25, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...
Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of H...
Management to host webinar for analysts and investors on July 25th Management to host webinar for analysts and investors on July 25th
New Strong Sell Stocks for July 7th
ACCD, DNLI, FSLY, FHB and GH have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2021.
Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in ...
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross...
Denali Therapeutics (DNLI) is Overbought: Is A Drop Coming?
Denali Therapeutics (DNLI) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Why Is Denali Therapeutics Inc. (DNLI) Up 10.7% Since Last Earnings Report?
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?
Biden's Budget May Boost These 3 Biotechs
It signals a big push toward curing a neurological disease with a massive market.
Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y
Denali (DNLI) posts a wider-than-expected loss in the first quarter of 2021 due to higher R&D costs.
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Misses Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -56.76% and -72.76%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross ...
Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End
Denali Therapeutics Inc (NASDAQ: DNLI) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The drug is being developed in collaboration with Biog...